Role of intravenous vitamin C on outcomes in hospitalized patients with moderate or severe COVID-19: a real life data of Turkish patients.

IF 4.6 2区医学 Q2 IMMUNOLOGY

Inflammopharmacology Pub Date : 2024-11-13 DOI:10.1007/s10787-024-01597-7

Burak Uz, Özgür İnce, Can Gümüş, Feyzi Gökosmanoğlu, Emrah Gökay Özgür, Gülnaz Nural Bekiroğlu

{"title":"Role of intravenous vitamin C on outcomes in hospitalized patients with moderate or severe COVID-19: a real life data of Turkish patients.","authors":"Burak Uz, Özgür İnce, Can Gümüş, Feyzi Gökosmanoğlu, Emrah Gökay Özgür, Gülnaz Nural Bekiroğlu","doi":"10.1007/s10787-024-01597-7","DOIUrl":null,"url":null,"abstract":"Background: We aimed to examine the efficacy of intravenous vitamin C (IV-VC) in the treatment of hospitalized patients with moderate or severe COVID-19.Method: We conducted a single-center and retrospective study including patients with COVID-19 diagnosis who were hospitalized. Patients were categorized into three groups as those who received low-dose (LDVC group, 2 g/day, n = 183) or high-dose IV-VC (HDVC group, 25 g/day, n = 41) and who did not receive IV-VC (control group, n = 46).Results: 270 patients aged 19-97 years were enrolled. The median length of stay (LOS) was significantly high (9 days) in patients treated with high-dose VC when compared to patients treated with low-dose VC and control patients (6 vs 5 days, respectively). Need for intensive care unit (ICU) transfer was found to be significantly low in patients treated with low-dose VC (25.7%); contrarily, control patients had significantly higher rates of ICU transfer (67.4%), when compared to patients treated with high-dose VC (39%). Mortality of the LDVC group was significantly lower than that of the HDVC group (11.5 vs 29.3%). However, mortality rates were similar between the control and HDVC groups (21.7 vs 29.3%). According to the multivariate stepwise logistic regression mortality analysis, percent of change (∆%)-BUN was the most significant variable (p < 0.001), the second significant variable was ∆%-AST (p = 0.002), the third significant variable was respiratory distress (p = 0.002), and the fourth significant variable was the IV-VC groups (p = 0.017). The mortality risk of those in the LDVC group was 10.2 times low compared to the control group. Similarly, the risk of mortality in the HDVC group was 6.5 times lower than that of the control group.Conclusion: Especially low and continious doses of IV-VC suggest fewer days of in-hospital LOS and survival benefit in hospitalized patients with moderate and severe COVID-19. Logistic regression analysis revealed that high-dose VC supplementation also had a mortality-reducing effect.","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-024-01597-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: We aimed to examine the efficacy of intravenous vitamin C (IV-VC) in the treatment of hospitalized patients with moderate or severe COVID-19.

Method: We conducted a single-center and retrospective study including patients with COVID-19 diagnosis who were hospitalized. Patients were categorized into three groups as those who received low-dose (LDVC group, 2 g/day, n = 183) or high-dose IV-VC (HDVC group, 25 g/day, n = 41) and who did not receive IV-VC (control group, n = 46).

Results: 270 patients aged 19-97 years were enrolled. The median length of stay (LOS) was significantly high (9 days) in patients treated with high-dose VC when compared to patients treated with low-dose VC and control patients (6 vs 5 days, respectively). Need for intensive care unit (ICU) transfer was found to be significantly low in patients treated with low-dose VC (25.7%); contrarily, control patients had significantly higher rates of ICU transfer (67.4%), when compared to patients treated with high-dose VC (39%). Mortality of the LDVC group was significantly lower than that of the HDVC group (11.5 vs 29.3%). However, mortality rates were similar between the control and HDVC groups (21.7 vs 29.3%). According to the multivariate stepwise logistic regression mortality analysis, percent of change (∆%)-BUN was the most significant variable (p < 0.001), the second significant variable was ∆%-AST (p = 0.002), the third significant variable was respiratory distress (p = 0.002), and the fourth significant variable was the IV-VC groups (p = 0.017). The mortality risk of those in the LDVC group was 10.2 times low compared to the control group. Similarly, the risk of mortality in the HDVC group was 6.5 times lower than that of the control group.

Conclusion: Especially low and continious doses of IV-VC suggest fewer days of in-hospital LOS and survival benefit in hospitalized patients with moderate and severe COVID-19. Logistic regression analysis revealed that high-dose VC supplementation also had a mortality-reducing effect.

查看原文本刊更多论文

静脉注射维生素 C 对中度或重度 COVID-19 住院患者疗效的影响：土耳其患者的真实数据。

背景我们旨在研究静脉注射维生素 C（IV-VC）治疗中度或重度 COVID-19 住院患者的疗效：我们进行了一项单中心回顾性研究，研究对象包括确诊为 COVID-19 的住院患者。患者被分为三组，即接受低剂量（LDVC 组，2 克/天，n = 183）或高剂量 IV-VC （HDVC 组，25 克/天，n = 41）治疗的患者，以及未接受 IV-VC 治疗的患者（对照组，n = 46）。与接受低剂量 VC 治疗的患者和对照组患者（分别为 6 天和 5 天）相比，接受高剂量 VC 治疗的患者的中位住院时间（LOS）明显较长（9 天）。研究发现，接受低剂量 VC 治疗的患者需要转入重症监护室（ICU）的比例明显较低（25.7%）；相反，对照组患者转入重症监护室的比例（67.4%）明显高于接受高剂量 VC 治疗的患者（39%）。低剂量VC组的死亡率明显低于高剂量VC组（11.5% 对 29.3%）。然而，对照组和 HDVC 组的死亡率相似（21.7% 对 29.3%）。根据多变量逐步逻辑回归死亡率分析，血清白蛋白变化百分比（∆%）是最显著的变量（p 结论：血清白蛋白变化百分比（∆%）对死亡率有显著影响：对于中度和重度 COVID-19 住院患者来说，低剂量和持续的静脉输液可缩短住院时间，并提高生存率。逻辑回归分析显示，大剂量补充 VC 也有降低死亡率的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY

CiteScore

8.00

自引率

3.40%

发文量

200

期刊介绍： Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]